GeniPhys
Private Company
Funding information not available
Overview
GeniPhys, founded in 2018 and based in San Diego, is a private biotechnology company pioneering a novel polymerizable collagen platform called Collymer™. The technology enables the custom fabrication of collagen-based scaffolds that promote regenerative healing without a foreign body response, differentiating it from conventional collagen biomaterials. The company has achieved an initial FDA 510(k) clearance for its Collymer SAS product and is positioned to address significant unmet needs in wound management and soft tissue reconstruction. GeniPhys operates as a platform technology company, aiming to be a global supplier of its polymerizable collagen while pursuing strategic partnerships to develop next-generation engineered solutions.
Technology Platform
Patented Collymer™ technology: a highly purified, polymerizable collagen protein that forms customizable, non-inflammatory fibrillar scaffolds to support regenerative tissue healing.
Opportunities
Risk Factors
Competitive Landscape
GeniPhys competes in the broad collagen and advanced biomaterials space, facing competition from large players like Integra LifeSciences, Baxter, and Collagen Solutions, as well as numerous startups. Its key competitive advantage is the claimed non-inflammatory and regenerative mode of action of its polymerizable collagen, which contrasts with the typical foreign body response elicited by many existing scaffolds.